Pipeline
Targeted therapeutics for underserved oncology patients
9Bio is committed to advancing highly selective, tumor-targeted therapeutics to broaden the transformative impact of cutting-edge oncology treatments to more patients. Our mission is guided by two key objectives.
First, we leverage our innovative platform to minimize off-tumor target engagement and develop antibody-drug conjugates (ADCs) for tumor antigens previously deemed undruggable due to partial peripheral expression. This approach addresses critical unmet needs in cancer indications where five-year survival rates remain unacceptably low.
Second, by enhancing specificity, we aim to improve the tolerability of our therapeutics, making them accessible to patients who are either contraindicated or often forced to discontinue treatment due to complications arising from comorbidities.
Through these efforts, we strive to advance clinically impactful, broadly applicable, and inclusive therapies — offering renewed hope to cancer patients and their families.
We focus on unlocking the potential of innovative therapeutic modalities, while also leveraging pragmatic value generation of proven targets.
Oncology Therapeutics
ADC targeting tumor and immune cells
Target indication: Liver and muscle invasive bladder cancers
Our lead program capitalizes on our tumor-selective technology to engineer an ADC that kills both cancer and tumor-subverted immune cells, while preserving the balance of the immune system in healthy tissues.
ADC rescuing failed clinical asset
Target indication: Head and neck and metastatic breast cancers
Our engineered ADC targets a promising tumor antigen associated with clinical efficacy, but which was abandoned after Phase 1 clinical trials due to on-target, off-tumor activity and toxicity.
The program is being developed in collaboration with our partners at the National Research Council Canada (NRC).
Cytokine leveraging a novel MoA
Target indication: Stomach and esophageal cancers
This engineered, first-in-class cytokine is designed for cancers refractory to existing therapies via a pioneering mechanism of action (MoA), which has to date remained underexploited due to its toxicity.